Incyte Announces Topline Results From Phase 3 Trial Evaluating Ruxolitinib Cream In Children With Atopic Dermatitis
Portfolio Pulse from Happy Mohamed
Incyte (NASDAQ:INCY) has announced positive topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura®) in children with atopic dermatitis (AD). The study met its primary endpoint, showing significantly more patients treated with ruxolitinib cream achieved Investigator's Global Assessment Treatment Success than those treated with a non-medicated cream. The safety profile of ruxolitinib cream is consistent with previous data, and no new safety signals were observed.
July 11, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Incyte's positive results from its Phase 3 study of ruxolitinib cream for children with atopic dermatitis could potentially boost the company's stock in the short term.
The positive results from the Phase 3 study of ruxolitinib cream indicate that the product is effective and safe for use in children with atopic dermatitis. This could potentially lead to increased sales and revenue for Incyte, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100